Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study [Urologic Oncology]

Conclusion Atezolizumab demonstrated a manageable safety profile and promising antitumor activity in patients with metastatic RCC. Correlative studies identified potential predictive and pharmacodynamic biomarkers. These results have guided ongoing studies and combinations with atezolizumab in RCC.
Source: Journal of Clinical Oncology - Category: Cancer & Oncology Authors: Tags: Clinical Trials, Phase I and Clinical Pharmacology, Translational Oncology, Genitourinary, Cancer Biomarkers, Gene Expression and Profiling, Immunology/Immunobiology, Phase I and Clinical Pharmacology Urologic Oncology Source Type: research